• Biosergen said trading in BTA paid subscribed shares will end once its rights issue is registered and BTAs convert into shares.
• Registration with the Swedish Companies Registration Office is expected around Sept. 10, 2026.
• The rights issue was oversubscribed by about 152%, raising about SEK 39.9 million before transaction costs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biosergen AB published the original content used to generate this news brief via Cision (Ref. ID: 20260828:BIT:3616:0) on August 28, 2026, and is solely responsible for the information contained therein.